Status:
COMPLETED
AZD6244 Versus Pemetrexed (Alimta®) in Patients With Non-small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen
Lead Sponsor:
AstraZeneca
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to assess the effect and safety of AZD6244(ARRY-142886)versus pemetrexed in the second or third line treatment of advanced Non-Small Cell Lung Cancer. Following baseline a...
Eligibility Criteria
Inclusion
- Diagnosed with non-small cell lung cancer
- Previously received one or two chemotherapeutic treatments
Exclusion
- Previous therapy with MEK inhibitor or pemetrexed
- Any recent surgery, unhealed surgical incision or severe condition such as uncontrolled cardiac disease or chronic gastrointestinal diseases
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
88 Patients enrolled
Trial Details
Trial ID
NCT00372788
Start Date
August 1 2006
End Date
December 1 2008
Last Update
August 13 2014
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Los Angeles, California, United States
2
Research Site
Ann Arbor, Michigan, United States
3
Research Site
New York, New York, United States
4
Research Site
Nashville, Tennessee, United States